RDHL Redhill Biopharma Ltd.

8.25
-0.17  -2%
Previous Close 8.42
Open 8.47
Price To Book 5.89
Market Cap 234041701
Shares 28,368,691
Volume 32,786
Short Ratio
Av. Daily Volume 136,522

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated mid-2019.
RHB-204
Nontuberculous mycobacteria (NTM) infections
Phase 2a enrollment to be completed mid-2019.
YELIVA
Cholangiocarcinoma
Phase 1/2 poster presentation at EORTC-NCI-AACR November 16, 2018.
YELIVA
Refractory or relapsed multiple myeloma - cancer
NDA resubmission announced November 1, 2017. Noted December 5, 2017 that an Incomplete Response Letter has been received from the FDA and termination of license agreement with IntelGenx Corp.
RIZAPORT (RHB-103)
Migraine
Phase 3 data released July 30, 2018. Primary endpoint met but further trial required.
RHB-104 MAP US
Crohn’s disease
Phase 3 trial met primary endpoint. NDA filing 1H 2019.
RHB-105 - ERADICATE Hp 2
H. pylori
Phase 3 top-line data released June 14, 2017 - primary endpoint met. Additional Phase 3 trial planned.
BEKINDA -GUARD
Gastroenteritis
Phase 2 top-line data released October 3, 2017 - primary endpoint met (borderline) - p=0.05. Follow up analysis identfied p value = 0.036. Phase 3 trial planned.
BEKINDA
IBS-D
Phase 2 initiated October 2016.
YELIVA
Hepatocellular carcinoma (HCC) - cancer